Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
Vicki OsborneMiranda DaviesSamantha LaneAlison EvansJacqueline DenyerSandeep DhandaDebabrata RoySaad ShakirPublished in: Drug safety (2020)
Based on currently available data, there was no clear benefit for the use of lopinavir-ritonavir compared to standard of care in severe COVID-19. Risk data suggested a possible decrease in serious adverse events. There was a reduction in acute respiratory distress syndrome with lopinavir-ritonavir in one study. Overall, the benefit-risk profile for lopinavir-ritonavir in severe COVID-19 cannot be considered positive until further efficacy and effectiveness data become available.
Keyphrases
- coronavirus disease
- acute respiratory distress syndrome
- sars cov
- electronic health record
- risk assessment
- antiretroviral therapy
- big data
- extracorporeal membrane oxygenation
- mechanical ventilation
- healthcare
- randomized controlled trial
- early onset
- respiratory syndrome coronavirus
- heavy metals
- quality improvement
- intensive care unit
- data analysis
- artificial intelligence
- chronic pain